Chronic lymphocytic leukemia (CLL): Update Bulletin #2
This edition presents key opinion leader (KOL) views on recent developments in the chronic lymphocytic leukaemia (CLL) market. Topics covered include: full results from the Phase III study of AbbVie/Roche’s Venclexta/Venclyxto (venetoclax) in combination with Rituxan/MabThera (rituximab; Roche) presented at the ASH meeting in December 2017; the initiation of a Phase III study investigating BeiGene’s novel Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in patients with relapsed/refractory CLL; Phase I/II results for Juno Therapeutics/Celgene’s JCAR014; and pilot trial results for an anti-CD19 CAR-T cell therapy in combination with Imbruvica (ibrutinib; Janssen Biotech/AbbVie) in patients with high-risk CLL.
In light of the positive results for Venclexta/Rituxan in the MURANO study, do KOLs envisage any changes to the second-line treatment regimen for CLL?
Do KOLs think it will be possible to overcome the side effects associated with the use of Venclexta/Rituxan?
If Venclexta/Rituxan is approved for treating patients with relapsed/refractory CLL, how widespread will its use become and why?
Will zanubrutinib’s selectivity for BTK inhibition translate into a clinically meaningful benefit for patients with CLL?
What role will zanubrutinib play within the CLL setting, if approved, and how well will it compete with other BTK inhibitors?
Will the toxicity associated with the use of anti-CD19 CAR-T cells confine their role to one of salvage therapy for CLL?
Do KOLs think that combining anti-CD19 CAR-T cells with Imbruvica will provide any therapeutic advantages for patients with CLL?
Apart from CD19, are there any other molecules which can be identified by KOLs as potentially effective therapeutic targets for CAR-T cell therapy?